Alzheimers Association Research Initiatives

Dean M. Hartley, Ph.D. Director of Scientific Director Alzheimers Association

1

Our vision is a world without Alzheimers disease

Our goals: Advance research Provide care and support Increase Concern & Awareness Public Policy & Advocacy Efforts

Alzheimers Association is the global leader in Alzheimer research.

Amyloid Imaging Taskforce (AIT)

A New Research Ini/a/ve Down Syndrome & Alzheimers disease

ALZHEIMERS ASSOCIATION, LINDA CRNIC INSTITUTE FOR DOWN SYNDROME, AND GLOBAL DOWN SYNDROME FOUNDATION LAUNCH NEW RESEARCH GRANTS PROGRAM

Initial $1.2 million aims to fund research to better treat Alzheimers in people with Down syndrome and the general population

The challenge began 100 years ago

November 1906: Alois Alzheimer tangles presented first case in Germany 51-year-old Auguste D. had profound memory loss, confusion, language difficulty, unfounded suspicions about husband and hospital staff Her young age made Alzheimer plaques think Auguste had a rare disease associated with middle age

Continuum of Alzheimers Disease

Normal Alzheimers disease

Adapted from Sperling et al. 2011 6

The Dominantly Inherited Alzheimer Network (DIAN) Observational Trial

Logical Memory
20 15 10 5 0 -30 -20 -10 0 10 20 Muta/on Carriers Non-Carriers 1.4 1.2 1 0.8 0.6 0.4 -30 -20 -10 0 10 20

Beta-Amyloid Deposition
Muta/on Carriers Non-Carriers

Est. Years Before Clinical Onset

Est. Years Before Clinical Onset

Bateman et al. (2012) N Eng J Med 367: 795- 804 www.alz.org 7

DIAN-Trial Unit
Alzheimers Association help to initiate the trial: $4.2M grant
Three simultaneous trials to test potential therapies:
Gantenerumab (Roche, Monoclonal antibody to AB) Solaneuzumab (Lilly, Monoclonal antibody to AB) TBD

Adaptive Trial Design Condenses the timeline Trial began March, 2013

Genetic Links to Alzheimers and Down Syndrome

NATURE REVIEWS | DRUG DISCOVERY VOLUME 11 | SEPTEMBER 2012 | 655

10